HAGGERTY POLICY SOLUTIONS for CALIFORNIA LIFE SCIENCES
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
FDA User Fee Reauthorization Act of 2022 - Reauthorization of PDUFA, MDUFA, and BSFUA - Accelerated approval, clinical trial diversity, medtech issues such as change control plans and foreign inspections certificates COVID 19 supplemental and pandemic efforts Pharmacy Benefit Manager (BPM) transparency
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEANNE HAGGERTY | — |
Taxation/Internal Revenue Code TAX
R&D Tax Credit Reauthorization Orphan drug tax credit generally
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEANNE HAGGERTY | — |
Medicare/Medicaid MMM
Inflation Reduction Act - all drug pricing provisions CMS proposed rule on Transitional Coverage of Emerging Technologies (TCET) Administration's EO on Prescription Drug Pricing
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEANNE HAGGERTY | — |
Trade (domestic/foreign) TRD
Administration's support of WTO proposal on TRIPS waiver for COVID vaccines and therapies
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEANNE HAGGERTY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.